Relationship between JAK2V617F mutation, allele burden and coagulation function in Ph-negative myeloproliferative neoplasms

References

• Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013;122(13):2176–2184. doi: 10.1182/blood-2013-03-460154
   PubMed Web of Science ®Google Scholar
• Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006;355(23):2452–2466. doi: 10.1056/NEJMra063728
   PubMed Web of Science ®Google Scholar
• Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224–2232. doi: 10.1200/JCO.2005.07.062
   PubMed Web of Science ®Google Scholar
• Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054–1061. doi: 10.1016/S0140-6736(05)74230-6
   PubMed Web of Science ®Google Scholar
• Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379–2390. doi: 10.1056/NEJMoa1311347
   PubMed Web of Science ®Google Scholar
• Rumi E, Pietra D, Guglielmelli P, et al. Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. Blood. 2013;121(21):4388–4395. doi: 10.1182/blood-2013-02-486050
   PubMed Web of Science ®Google Scholar
• Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779–1790. doi: 10.1056/NEJMoa051113
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144–1148. doi: 10.1038/nature03546
   PubMed Web of Science ®Google Scholar
• Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366(9501):1945–1953. doi: 10.1016/S0140-6736(05)67785-9
   PubMed Web of Science ®Google Scholar
• Antonioli E, Guglielmelli P, Pancrazzi A, et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia. 2005;19(10):1847–1849. doi: 10.1038/sj.leu.2403902
   PubMed Web of Science ®Google Scholar
• Zhou J, Ye Y, Zeng S, et al. Impact of JAK2 V617F mutation on hemogram variation in patients with non-reactive elevated platelet counts. PLoS One. 2013;8(2):e57856. doi: 10.1371/journal.pone.0057856
   PubMed Web of Science ®Google Scholar
• Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, et al. Automated assessment of the neutrophil and platelet activation status in patients with essential thrombocythemia. Platelets. 2012;23(5):336–343. doi: 10.3109/09537104.2011.630112
   PubMed Web of Science ®Google Scholar
• Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, et al. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden. Am J Hematol. 2009;84(2):102–108. doi: 10.1002/ajh.21338
   PubMed Web of Science ®Google Scholar
• Marchetti M, Castoldi E, Spronk HM, et al. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood. 2008;112(10):4061–4068. doi: 10.1182/blood-2008-06-164087
   PubMed Web of Science ®Google Scholar
• Hexner EO. JAK2 V617F: implications for thrombosis in myeloproliferative diseases. Curr Opin Hematol. 2007;14(5):450–454. doi: 10.1097/MOH.0b013e3282861d1b
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Antonioli E, Guglielmelli P, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia. 2007;21(9):1952–1959. doi: 10.1038/sj.leu.2404854
   PubMed Web of Science ®Google Scholar
• Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an international prognostic score of thrombosis in world health organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128–5133; quiz 5252. doi: 10.1182/blood-2012-07-444067
   PubMed Web of Science ®Google Scholar
• Barbui T, Falanga A. Molecular biomarkers of thrombosis in myeloproliferative neoplasms. Thromb Res. 2016;140(Suppl. 1):S71–S75. doi: 10.1016/S0049-3848(16)30102-5
   PubMedGoogle Scholar
• Borowczyk M, Wojtaszewska M, Lewandowski K, et al. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms. Thromb Res. 2015;135(2):272–280. doi: 10.1016/j.thromres.2014.11.006
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R. et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi: 10.1182/blood-2016-03-643544
   PubMed Web of Science ®Google Scholar
• Latagliata R, Stagno F, Annunziata M, et al. Frontline dasatinib treatment in a “real-life” cohort of patients older than 65 years with chronic Myeloid Leukemia. Neoplasia. 2016;18(9):536–540. doi: 10.1016/j.neo.2016.07.005
   PubMed Web of Science ®Google Scholar
• Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387–397. doi: 10.1016/j.ccr.2005.03.023
   PubMed Web of Science ®Google Scholar
• Zhang SP, Li H, Lai RS. Detection of JAK2 V617F mutation increases the diagnosis of myeloproliferative neoplasms. Oncol Lett. 2015;9(2):735–738.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Rumi E, Pietra D, et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood. 2006;107(9):3676–3682. doi: 10.1182/blood-2005-09-3826
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia. 2008;22(7):1299–1307. doi: 10.1038/leu.2008.113
   PubMed Web of Science ®Google Scholar
• Fantasia F, Di Capua EN, Cenfra N, et al. A highly specific q-RT-PCR assay to address the relevance of the JAK2WT and JAK2V617F expression levels and control genes in Ph-negative myeloproliferative neoplasms. Ann Hematol. 2014;93(4):609–616. doi: 10.1007/s00277-013-1920-0
   PubMed Web of Science ®Google Scholar
• Edahiro Y, Morishita S, Takahashi K, et al. JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan. Int J Hematol. 2014;99(5):625–634. doi: 10.1007/s12185-014-1567-1
   PubMed Web of Science ®Google Scholar
• Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128(3):275–290. doi: 10.1111/j.1365-2141.2004.05277.x
   PubMed Web of Science ®Google Scholar
• Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood. 2007;109(6):2310–2313. doi: 10.1182/blood-2006-09-046342
   PubMed Web of Science ®Google Scholar
• Falanga A, Marchetti M, Evangelista V, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood. 2000;96(13):4261–4266.
   PubMed Web of Science ®Google Scholar